In a recent study posted in the Research Square* preprint server, which is under consideration at Scientific Reports, researchers examined the detailed mechanisms of ‘cytokine storm’ that induces ...

A new type of anti-interleukin-6 (IL-6) biologic called olokizumab was as effective as adalimumab (Humira) in rheumatoid arthritis patients who needed a step up from methotrexate monotherapy, results ...

The maternal and neonatal outcomes in pregnant women treated with anti–interleukin (IL)-6 therapy for COVID-19 are largely favorable, with transient neonatal cytopenia observed in around one third of ...

In 1973, interleukin 6 (IL-6) was detected as a soluble factor that is secreted by T cells. It is crucial for the generation of antibodies through B cells. The IL-6 signaling pathway has become a ...

Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...

Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6). Researchers at The University of Texas ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. WASHINGTON — Patients with inflammatory arthritis who ...

Sanofi and Regeneron are putting their hopes in IL-6 inhibitor Kevzara as a possible therapy for COVID-19 with clinical trials underway. Now, a second IL-6 med rolling into trial in an Italian ...

Interleukin 6 receptor (IL-6r) inhibition is a promising approach for the treatment of calcium pyrophosphate deposition disease (CPPD), although no prospective studies have been conducted to date.

Regeneron and Sanofi posted disappointing results from a Phase II trial testing their arthritis drug Kevzara in people hospitalized with COVID-19. Kevzara is an antibody that binds and blocks the IL-6 ...